Boehringer Ingelheim Animal Health has released to U.S. veterinarians the first FDA-approved liquid solution for the control of feline systemic hypertension.
Semintra (telmisartan oral solution) earned U.S. Food and Drug Administration approval in May 2018. The drug was introduced to a select number of European countries in September.
“With Semintra, we offer a pet owner-friendly, easy-to-give solution to help raise the quality of life of cats with hypertension, while providing reliable long-term blood pressure control,” said Shawn Hooker, global head of the Pet Veterinarian Business Unit.
The active ingredient, telmisartan, is an angiotensin II receptor blocker (ARB) that reduces blood pressure by relaxing blood vessels, the FDA reported.
The oral solution may be administered into a cat’s mouth or on top of a small amount of food, the FDA added.